FY2026 EPS Estimates for Surmodics, Inc. (NASDAQ:SRDX) Cut by Barrington Research

Surmodics, Inc. (NASDAQ:SRDX) – Equities research analysts at Barrington Research reduced their FY2026 earnings per share (EPS) estimates for Surmodics in a report issued on Thursday, August 1st. Barrington Research analyst M. Petusky now forecasts that the company will post earnings per share of $0.87 for the year, down from their previous forecast of $0.88. Barrington Research currently has a “Market Perform” rating on the stock. The consensus estimate for Surmodics’ current full-year earnings is ($0.51) per share.

SRDX has been the topic of several other research reports. Lake Street Capital reiterated a “hold” rating and issued a $43.00 target price on shares of Surmodics in a research note on Wednesday, May 29th. Needham & Company LLC reaffirmed a “hold” rating on shares of Surmodics in a research report on Monday. Sidoti reiterated a “neutral” rating and set a $43.00 target price on shares of Surmodics in a research note on Wednesday, May 29th. Finally, StockNews.com started coverage on Surmodics in a research note on Saturday. They issued a “hold” rating for the company. Five analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $50.00.

Surmodics Stock Performance

Shares of SRDX stock opened at $41.25 on Monday. The company has a market capitalization of $588.64 million, a price-to-earnings ratio of 43.42 and a beta of 1.18. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.59 and a current ratio of 3.98. Surmodics has a one year low of $25.17 and a one year high of $42.44. The company’s 50-day moving average is $41.86 and its 200 day moving average is $34.62.

Institutional Investors Weigh In On Surmodics

A number of large investors have recently added to or reduced their stakes in SRDX. Acadian Asset Management LLC boosted its stake in shares of Surmodics by 11.3% in the 1st quarter. Acadian Asset Management LLC now owns 408,779 shares of the company’s stock worth $11,988,000 after buying an additional 41,617 shares during the last quarter. Strs Ohio boosted its position in Surmodics by 97.2% in the fourth quarter. Strs Ohio now owns 7,100 shares of the company’s stock worth $258,000 after purchasing an additional 3,500 shares during the last quarter. Panagora Asset Management Inc. grew its stake in shares of Surmodics by 109.8% during the 4th quarter. Panagora Asset Management Inc. now owns 44,664 shares of the company’s stock valued at $1,624,000 after purchasing an additional 23,379 shares during the period. Hillsdale Investment Management Inc. increased its position in shares of Surmodics by 15.7% during the 4th quarter. Hillsdale Investment Management Inc. now owns 4,570 shares of the company’s stock valued at $166,000 after purchasing an additional 620 shares during the last quarter. Finally, US Bancorp DE lifted its stake in shares of Surmodics by 61.9% in the 4th quarter. US Bancorp DE now owns 16,190 shares of the company’s stock worth $589,000 after purchasing an additional 6,193 shares during the period. Institutional investors own 96.63% of the company’s stock.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).